COVID-19, Acute Lymphoblastic Leukemia and Down Syndrome: A Short Review
and a Case Report
Abstract
In late December 2019, Chinese citizens of the city of Wuhan, China, had
shown symptoms of viral pneumonia that were not very common, with
various presentations with different grades of severity, and poor
response to the regular treatment. With tremendous clinical and research
work, the causative of the disease outbreak has been identified as
COVID-19 and has been recognized as the novel coronavirus (SARS-CoV-2),
which later continued to make the headlines when the World Health
Organization announced it as a pandemic on March 11, 2020, after it had
hit many parts in the globe with worrying rates of morbidity and
mortality. Although available data has expressed that moderate or even
mild forms of the disease are expected amongst most of the pediatrics
cases, very limited data are available on the prognosis and the
complications of the disease on the immunocompromised, especially
oncology patients. We report a case of relapsed Precursor B-cell acute
lymphoblastic leukemia (ALL) of a child with Down syndrome (DS) and
COVID-19 and outline the treatment regimen that we used.